Shared on03 Sep 25Fair value Increased 1.17%
Both the Future P/E and Net Profit Margin for Fresenius SE KGaA remained essentially stable, underpinning the marginal increase in the consensus analyst price target from €49.04 to €49.61. What's in the News Fresenius is leading the EASYGEN consortium, a public-private EU-funded initiative aiming to accelerate and cost-optimize CAR-T cell therapy manufacturing, making it more accessible across Europe using modular, hospital-based platforms.
Shared on23 Apr 25Fair value Decreased 0.085%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 3.34%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 17%
AnalystConsensusTarget has decreased future PE multiple from 17.7x to 14.6x.
Shared on26 Mar 25Fair value Increased 27%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 7.97%
AnalystConsensusTarget has increased future PE multiple from 14.9x to 17.2x.
Shared on12 Mar 25Fair value Increased 85%
AnalystConsensusTarget has increased revenue growth from 2.6% to 4.5%, increased future PE multiple from 12.5x to 14.9x and decreased shares outstanding growth rate from 0.1% to 0.0%.